TY - JOUR T1 - Erenumab is effective in reducing migraine frequency and improving physical functioning JF - BMJ Evidence-Based Medicine JO - BMJ EBM SP - 76 LP - 76 DO - 10.1136/bmjebm-2018-110937 VL - 24 IS - 2 AU - Paolo Martelletti Y1 - 2019/04/01 UR - http://ebm.bmj.com/content/24/2/76.abstract N2 - Commentary on: Goadsby PJ, Reuter U, Hallström YA, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123-2132.Migraine presents an important social, economic and disability burden in 14% of affected population.1 The age range more compromised is under 50, which represents a burden in personal, social and working functioning.1 Migraine treatments are old and with low compliance by the patient for adverse events. Erenumab is a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRPr) showing promising evidences from a controlled trial in episodic migraine.2 This randomised, double-blind, multicentre, placebo-controlled trial of erenumab in episodic migraine has been carried out through the monthly subcutaneous administration of either erenumab or placebo for a 6-month period. In total, … ER -